摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5,12-diethyl-5-hydroxy-1,4,5,13-tetrahydro-3H,15H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione | 186668-44-0

中文名称
——
中文别名
——
英文名称
5,12-diethyl-5-hydroxy-1,4,5,13-tetrahydro-3H,15H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione
英文别名
10,20-Diethyl-20-hydroxy-17-oxa-3,13-diazapentacyclo[11.9.0.02,11.04,9.015,21]docosa-1(22),2,4,6,8,10,15(21)-heptaene-14,18-dione
5,12-diethyl-5-hydroxy-1,4,5,13-tetrahydro-3H,15H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione化学式
CAS
186668-44-0
化学式
C23H22N2O4
mdl
——
分子量
390.439
InChiKey
RTGGYXAOZKQTAX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    29
  • 可旋转键数:
    2
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    79.7
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    5,12-diethyl-5-hydroxy-1,4,5,13-tetrahydro-3H,15H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione 生成 3-[12-ethyl-8-(hydroxymethyl)-9-oxo-9,11-dihydroindolizino[1,2-b]quinolin-7-yl]-3-hydroxypentanoic acid
    参考文献:
    名称:
    Comptothecin analogues, preparation methods therefor, use thereof as drugs, and pharmaceutical compositions containing said analogues
    摘要:
    该化合物的结构如下所示,其中取代基的定义如规范中所述,以及其无毒、药用可接受的盐,可用于治疗病毒感染、寄生虫病和癌症的治疗。
    公开号:
    US06339091B1
  • 作为产物:
    描述:
    3-(12-Ethyl-8-hydroxymethyl-9-oxo-9,11-dihydro-indolizino[1,2-b]quinolin-7-yl)-3-hydroxy-pentanoic acid tert-butyl ester 在 盐酸 作用下, 以 二氯甲烷 为溶剂, 反应 16.0h, 生成 5,12-diethyl-5-hydroxy-1,4,5,13-tetrahydro-3H,15H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione
    参考文献:
    名称:
    Homocamptothecins:  Synthesis and Antitumor Activity of Novel E-Ring-Modified Camptothecin Analogues
    摘要:
    Homocamptothecin (hCPT), a camptothecin (CPT) analogue with a seven membered beta-hydroxylactone which combines enhanced plasma stability and potent topoisomerase I (Topo I)-mediated activity, is an attractive template for the elaboration of new anticancer agents. Like CPT, hCPT carries an asymmetric tertiary alcohol and displays stereoselective inhibition of Topo I. The preparation and biological screening of racemic hCPT analogues are described. The 10 hCPTs tested were better Topo I inhibitors than CPT. Fluorinated hCPTs 23c,d,f,g were found to have potent cytotoxic activity on A427 and PC-3 tumor cell lines. Their cytotoxicity remained high on the K562adr and MCF7mdr cell. lines, which overexpress a functionally active P-glycoprotein. Fluorinated hCPTs were more efficacious in vivo than CPT on HT-29 xenografts. In this model, a tumor growth delay of 25 days was reached with hCPT 23g at a daily dose of 0.32 mg/kg, compared to 4 days with CPT at 0.625 mg/kg. Thus difluorinated hCPT 23g warrants further investigation as a novel Topo I inhibitor with high cytotoxicity toward tumor cells and promising in vivo efficacy.
    DOI:
    10.1021/jm980400l
点击查看最新优质反应信息

文献信息

  • New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them
    申请人:——
    公开号:US20030004150A1
    公开(公告)日:2003-01-02
    A compound of the formula 1 wherein the substituents are defined as in the specification which compounds are useful in the treatment of cancer.
    其中取代基如规范中所定义的化合物的化学式,这些化合物在癌症治疗中很有用。
  • Compositions for improving lipid content in the blood
    申请人:SANKYO COMPANY, LIMITED
    公开号:US20030216357A1
    公开(公告)日:2003-11-20
    The present invention relates to compositions for lowering the total amount of cholesterol in the blood and methods of using the compositions. The compositions are a mixture of pravastatin and one or more vitamins selected from riboflavins, d-&agr;-tocopherols, ascorbic acids and inositol hexanicotinate.
    本发明涉及降低血液中胆固醇总量的组合物和使用组合物的方法。该组合物是普伐他汀和一种或多种维生素的混合物,这些维生素选自核黄素、d-&agr;-生育酚抗坏血酸和肌醇六烟酸酯。
  • US5994344A
    申请人:——
    公开号:US5994344A
    公开(公告)日:1999-11-30
  • US5981542A
    申请人:——
    公开号:US5981542A
    公开(公告)日:1999-11-09
  • US6313135B1
    申请人:——
    公开号:US6313135B1
    公开(公告)日:2001-11-06
查看更多